Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 12/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24558105 | 1.00 | KRAS (0.40) | KRASIDO1USP30HDAC6ESR2 | |
| SCHEMBL24558218 | 0.88 | KRAS (0.40) | KRASUSP30HDAC6ESR2DPP4 | |
| SCHEMBL24558408 | 0.88 | KRAS (0.40) | KRASUSP30HDAC6ESR2DPP4 | |
| SCHEMBL23512794 | 0.88 | KRAS (0.39) | KRASUSP30ESR2 | |
| SCHEMBL29693098 | 0.88 | KRAS (0.39) | KRASUSP30ESR2 | |
| SCHEMBL28654336 | 0.84 | KRAS (0.43) | KRASDPP4 | |
| SCHEMBL4411026 | 0.84 | USP30 (0.40) | KRASUSP30ESR2 | |
| SCHEMBL29693164 | 0.83 | KRAS (0.49) | KRASUSP30HDAC6 | |
| SCHEMBL24558243 | 0.83 | KRAS (0.49) | KRASUSP30HDAC6 | |
| SCHEMBL31236075 | 0.83 | SOS1 (0.41) | KRASIDO1USP30HDAC6DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| CN-113508118-B | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | KRAS 89/4885IDO1 4481/4885USP30 4265/4885 |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | KRAS 89/4885IDO1 4481/4885USP30 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.